Mok T, Peters S, Camidge DR, Noe J, et al. Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study. J Thorac Oncol 2021;16:259-268.
PMID: 33334571